Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2014; 20(28): 9611-9617
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9611
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9611
Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus
Piers Gatenby, Christine Caygill, Christine Wall, Santanu Bhatacharjee, James Ramus, Anthony Watson, Marc Winslet, Division of Surgery and Interventional Science, UCL, London, NW32QG, United Kingdom
Author contributions: All the authors contributed to substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published.
Supported by Barrett’s Oesophagus Campaign; the Wexham Gastrointestinal Trust; the Childwick Trust; the RL St J Harmsworth Memorial Research Fund; the David and Frederick Barclay Foundation
Correspondence to: Piers Gatenby, MD, Division of Surgery and Interventional Science, UCL, Royal Free Campus, Pond Street, London, NW32QG, United Kingdom. p.gatenby@ucl.ac.uk
Telephone: +44-20-74726223 Fax: +44-20-74726224
Received: November 5, 2013
Revised: February 7, 2014
Accepted: March 12, 2014
Published online: July 28, 2014
Processing time: 264 Days and 10.6 Hours
Revised: February 7, 2014
Accepted: March 12, 2014
Published online: July 28, 2014
Processing time: 264 Days and 10.6 Hours
Core Tip
Core tip: The mean life expectancy for patients at diagnosis of Barrett’s esophagus is 22 years. Based on current estimates for high-grade dysplasia and adenocarcinoma incidence, the lifetime risk of requiring an intervention for high-grade dysplasia or adenocarcinoma development based on data from recent meta-analyses is 1 in 5 to 1 in 6 and based on data from recent population-based studies is between 1 in 8 and 1 in 20.